Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

By G. Gravis, K. Fizazi, F. Joly, S. Oudard, F. Priou, B. Esterni, I. Latorzeff, R. Delva, I. Krakowski, B. Laguerre and 23 more. The Lancet Oncology, 2013

625 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/b0d79bb2b741d9db1c35ea209bd1ca81e8336f94

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Michel Bolla
2. N. Mottet
3. J. Bellmunt
4. Steven Joniau
5. Thomas Wiegel

In Pulmonary and Respiratory Medicine

1. Michel Bolla
2. N. Mottet
3. J. Bellmunt
4. Steven Joniau
5. Thomas Wiegel

Citations in the corpus

• Prostate Cancer (2018, neutral): “0009) after adjustment for D’Amico risk stratum, comorbidity, pathological features, and PSA doubling time [88].”
• EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. (2017, background): “In the GETUG 15 trial [58], all patients had newly diagnosed M1 PCa, either primary or after a primary treatment.”
• Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer (2017, neutral): “Bone pain 74 (12) 20 (3) 0 88 (15) 17 (3) 0”
• Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy (2017, neutral): “(%) Newly diagnosed node‐negative, nonmetastatic disease 256 (27) 253 (26) Newly diagnosed node‐positive, nonmetastatic disease 187 (20) 182 (19) Newly diagnosed metastatic disease 476 (50) 465 (48) Previously treated nonmetastatic disease 12 (1) 25 (3) Previously treated metastatic disease 26 (3) 3”